ZANTAC IN PLASTIC CONTAINER Drug Patent Profile
✉ Email this page to a colleague
When do Zantac In Plastic Container patents expire, and what generic alternatives are available?
Zantac In Plastic Container is a drug marketed by Pai Holdings Pharm and is included in one NDA.
The generic ingredient in ZANTAC IN PLASTIC CONTAINER is ranitidine hydrochloride. There are forty-three drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the ranitidine hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Zantac In Plastic Container
A generic version of ZANTAC IN PLASTIC CONTAINER was approved as ranitidine hydrochloride by SANDOZ on August 29th, 1997.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for ZANTAC IN PLASTIC CONTAINER?
- What are the global sales for ZANTAC IN PLASTIC CONTAINER?
- What is Average Wholesale Price for ZANTAC IN PLASTIC CONTAINER?
Summary for ZANTAC IN PLASTIC CONTAINER
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 77 |
| Clinical Trials: | 22 |
| Patent Applications: | 4 |
| DailyMed Link: | ZANTAC IN PLASTIC CONTAINER at DailyMed |
Recent Clinical Trials for ZANTAC IN PLASTIC CONTAINER
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Food and Drug Administration (FDA) | Phase 1 |
| Spaulding Clinical Research LLC | Phase 1 |
| Lisa Barrett | Phase 4 |
US Patents and Regulatory Information for ZANTAC IN PLASTIC CONTAINER
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pai Holdings Pharm | ZANTAC IN PLASTIC CONTAINER | ranitidine hydrochloride | INJECTABLE;INJECTION | 019593-002 | Sep 27, 1991 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Pai Holdings Pharm | ZANTAC IN PLASTIC CONTAINER | ranitidine hydrochloride | INJECTABLE;INJECTION | 019593-001 | Dec 17, 1986 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for ZANTAC IN PLASTIC CONTAINER
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Pai Holdings Pharm | ZANTAC IN PLASTIC CONTAINER | ranitidine hydrochloride | INJECTABLE;INJECTION | 019593-001 | Dec 17, 1986 | 4,128,658 | ⤷ Start Trial |
| Pai Holdings Pharm | ZANTAC IN PLASTIC CONTAINER | ranitidine hydrochloride | INJECTABLE;INJECTION | 019593-002 | Sep 27, 1991 | 4,128,658 | ⤷ Start Trial |
| Pai Holdings Pharm | ZANTAC IN PLASTIC CONTAINER | ranitidine hydrochloride | INJECTABLE;INJECTION | 019593-002 | Sep 27, 1991 | 4,128,659 | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for ZANTAC IN PLASTIC CONTAINER
See the table below for patents covering ZANTAC IN PLASTIC CONTAINER around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Australia | 7595581 | ⤷ Start Trial | |
| France | 2547727 | COMPOSITIONS PHARMACEUTIQUES | ⤷ Start Trial |
| United Kingdom | 1565966 | ⤷ Start Trial | |
| Denmark | 427282 | ⤷ Start Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch